WO2010100686A1 - コレスタノール誘導体の併用用途 - Google Patents
コレスタノール誘導体の併用用途 Download PDFInfo
- Publication number
- WO2010100686A1 WO2010100686A1 PCT/JP2009/004353 JP2009004353W WO2010100686A1 WO 2010100686 A1 WO2010100686 A1 WO 2010100686A1 JP 2009004353 W JP2009004353 W JP 2009004353W WO 2010100686 A1 WO2010100686 A1 WO 2010100686A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gal
- glcnac
- cancer
- anticancer
- chemotherapeutic agent
- Prior art date
Links
- 0 CC(C)CCC[C@@](C)[C@@](CC1)[C@@](C)(CC2)C1C(CC[C@](C)C1)C2CCC[C@]1O* Chemical compound CC(C)CCC[C@@](C)[C@@](CC1)[C@@](C)(CC2)C1C(CC[C@](C)C1)C2CCC[C@]1O* 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J17/005—Glycosides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
Definitions
- the present invention relates to a cancer chemotherapeutic agent, and more particularly to a cancer chemotherapeutic agent comprising a combination of a cholestanol derivative and an anticancer agent.
- the present invention relates to providing a cancer chemotherapeutic agent with reduced side effects and exhibiting excellent efficacy.
- G represents GlcNAc-Gal-, GlcNAc-Gal-Glc-, Fuc-Gal-, Gal-Glc-, Gal- or GlcNAc-.
- a cancer chemotherapeutic agent comprising a combination of a cholestanol derivative represented by the above or a cyclodextrin inclusion body thereof and an anticancer agent. 2) The cancer chemotherapeutic agent according to 1) above, wherein, in the general formula (1), G is GlcNAc-Gal- or GlcNAc-.
- the anticancer agent is one or more selected from the group consisting of paclitaxel, docetaxel, pemetrexed, 5-FU, cisplatin, oxaliplatin, cyclophosphamide, and irinotecan.
- the cancer chemotherapeutic agent according to any one of 1) to 6) above which is a kit comprising a drug comprising a cholestanol derivative and a drug comprising an anticancer agent.
- G represents GlcNAc-Gal-, GlcNAc-Gal-Glc-, Fuc-Gal-, Gal-Glc-, Gal- or GlcNAc-.
- G represents GlcNAc-Gal-, GlcNAc-Gal-Glc-, Fuc-Gal-, Gal-Glc-, Gal- or GlcNAc-.
- a combination of an anticancer agent and a cholestanol derivative represented by the formula: 11) Use of said 10) whose anticancer agent is 1 or more types selected from the group which consists of a taxane type anticancer agent, a pemetrexed compound, and fluorouracil.
- the anticancer agent is one or more selected from the group consisting of paclitaxel, docetaxel, pemetrexed, 5-FU, cyclophosphamide and irinotecan. 13) The following general formula (1):
- G represents GlcNAc-Gal-, GlcNAc-Gal-Glc-, Fuc-Gal-, Gal-Glc-, Gal- or GlcNAc-.
- a cancer chemotherapy comprising administering a cholestanol derivative represented by the above or a cyclodextrin inclusion body thereof in combination with an anticancer agent. 14) The cancer chemotherapy according to the above 13), wherein the cholestanol derivative or a cyclodextrin inclusion body thereof and the anticancer agent are administered simultaneously or separately at intervals.
- cancer chemotherapeutic agent and cancer chemotherapy of the present invention are used, it is possible to prevent or treat cancer safely and more efficiently.
- inoculation by the cancer cell inoculated intraperitoneally Graph showing survival rate of mice in colon 26 mouse peritoneal dissemination after administration of CDDP and GC-CD alone or in combination.
- the cholestanol derivative (1) used in the present invention is a known compound.
- GlcNAc-Gal- are preferably GlcNAc ⁇ 1,3-Gal ⁇ - or GlcNAc ⁇ 1,4-Gal ⁇ -, and those in which GlcNAc-Gal-Glc- are present.
- GlcNAc ⁇ 1,3-Gal ⁇ 1,4-Glc- preferably Fuc-Gal-, preferably Fuc ⁇ 1,3Gal-, and preferably Gal-Glc-, preferably Gal ⁇ 1,4Glc ⁇ -
- those that are Gal- are preferably Gal ⁇ - and those that are GlcNAc- are preferably GlcNAc ⁇ -.
- the cholestanol derivative can be produced, for example, by the method described in Patent Documents 1-4 or a method analogous thereto.
- the cyclodextrin inclusion body can be used as a cholestanol derivative in the present invention.
- Cyclodextrin is considered to be involved in the diameter of the guest molecule to be included, or the Van der Waals force with the guest molecule and the hydrogen bond with the cyclodextrin-derived hydroxyl group. Although it is not a thing, a favorable inclusion complex is formed about the cholestanol derivative of this invention.
- Examples of the cyclodextrin in the cyclodextrin inclusion body of the present invention include cyclodextrins such as ⁇ -cyclodextrin, ⁇ -cyclodextrin, and ⁇ -cyclodextrin, as well as methyl- ⁇ -cyclodextrin, 2-hydroxypropyl- ⁇ , and the like. Cyclodextrin derivatives such as cyclodextrin, monoacetyl- ⁇ -cyclodextrin, 2-hydroxypropyl- ⁇ -cyclodextrin are included. Of these, 2-hydroxypropyl- ⁇ -cyclodextrin is preferred from the viewpoint of improving solubility.
- Such a cyclodextrin inclusion body is prepared, for example, by preparing a suitable aqueous solution (for example, 20 to 40%) of cyclodextrins or a derivative thereof, adding the cholestanol derivative of the present invention to this, and stirring. Can do.
- the concentration of the cholestanol derivative (1) used here may be a concentration at which the cholestanol derivative can form an inclusion body with cyclodextrin, and is usually about 1 to 50% by mass, preferably about 10 to 30% by mass. .
- the cyclodextrin clathrate thus obtained can be effectively soluble in water since it is readily soluble in water. There is also an advantage that stable evaluation can be performed in an in vitro test system.
- the cholestanol derivative (1) can reach the site of action more efficiently by using a liposome preparation. It is also possible to perform stable evaluation in an in vitro test system.
- a liposome preparation is preferably a liposome containing the cholestanol derivative of the present invention, a membrane component substance and an aliphatic or aromatic amine.
- the content of the cholestanol derivative in the liposome preparation is desirably 0.3 to 2.0 mol, preferably 0.8 to 1.5 mol, with respect to 1 mol of the membrane component substance.
- membrane component substances include phospholipids, and natural and synthetic phospholipids such as phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol and phosphatidic acid, and mixtures thereof, as well as processed natural such as aqueous lecithin.
- Phospholipids can be preferably used. More preferable examples include 1 ⁇ dipalmitoyl phosphatidylcholine (DPPC), which is a phosphatidylcholine.
- DPPC dipalmitoyl phosphatidylcholine
- An aliphatic or aromatic amine is a substance added mainly to positively charge the surface of the lipid membrane.
- examples of such amines include aliphatic amines such as stearylamine and oleylamine, and aromatic amines such as fluoreneethylamine, and stearylamine can be particularly preferably used.
- the amine is contained in an amount of 0.04 to 0.15 mol, preferably 0.1 to 0.15 mol, relative to 1 mol of the membrane component substance (phospholipid).
- cholesterol may be added to the liposome as needed as a stabilizer of the membrane structure.
- aqueous solution in which the membrane component is dispersed water, physiological saline, various buffer solutions, saccharide aqueous solutions and mixtures thereof are preferably used.
- a buffer solution having a buffering action in the vicinity of the body fluid hydrogen ion concentration is preferably used regardless of whether it is organic or inorganic, and examples thereof include a phosphate buffer.
- the preparation of the liposome is not particularly limited, and a general method can be used.
- a general method can be used.
- anticancer agent used in combination with the cholestanol derivative (1) or its cyclodextrin inclusion body various anticancer agents known as cancer chemotherapeutic agents can be used, and a standard established in cancers to be treated.
- a therapeutic agent can be suitably used.
- alkylating agents such as cyclophosphamide, ifosfamide, melphalan, L-PAM, busulfan, carboquinone, etc .; 6-mercaptopurine (6- Mercaptopurine, 6-MP), methotrexate (MTX), 5-fluorouracil (5-FU), tegafur, enocitabine (Enocitabine, BHAC), pemetrexed compound (pemetrexed, MT, etc.)
- Antimetabolite Actinomycin D, Daunorubicin, Bleomycin, Peplomycin, Mitomycin C, Aclarubicin, Neocarzinostatin, NCS Anticancer antibiotics such as; Vincristine, Vindesine, Vinblastine, Taxane anticancer drugs (Taxotere (Docetaxel, Docetaxel), Taxol (Paclitaxel, TXL, Paclitaxel), etc.), Irinotecan, CPT-11, etc .; Examples
- the cholestanol derivative (1) or its cyclodextrin inclusion body is used in combination with an anticancer agent, the proliferation of various cancer cells is strongly suppressed as compared with the case where each is administered alone, as shown in the Examples below. Therefore, the chemotherapy which combined these can improve effectiveness and reduction of a side effect, and is very useful, and the pharmaceutical containing these is useful as a cancer chemotherapeutic agent.
- Cancers that can be effectively treated by the application of the cancer chemotherapeutic agent of the present invention are not limited, but particularly gastric cancer, colon cancer, pancreatic cancer, uterine cancer, ovarian cancer, lung cancer, gallbladder cancer, esophageal cancer, Examples include malignant tumors such as liver cancer, breast cancer, mesothelioma, and prostate cancer.
- cancer chemotherapeutic agent of the present invention is formulated into a single dosage form (one-drug form) at an appropriate blending ratio, each effective amount of each of the above components as a combination drug. It may be a kit (two-dose form) in which a drug containing an amount is formulated separately, and can be used separately at the same time or at intervals.
- the dosage form of the above preparation is not particularly limited, as is the case with general pharmaceutical preparations, and may be any of solid preparations such as tablets, liquids such as injections, and on-the-fly solubilizing agents such as dry powders.
- the dosage form of such a preparation is not limited, and may be administered by an appropriate route according to the dosage form.
- an injection is administered intravenously, intramuscularly, subcutaneously, intradermally, or intraperitoneally. Can be administered orally or enterally.
- Each preparation can be prepared according to a conventional method, and all fillers, fillers, and other excipients or diluents commonly used as a preparation carrier can be used.
- a preparation carrier for example, when preparing an oral solid preparation, after adding an excipient, if necessary, a binder, a disintegrant, a lubricant, a colorant, a corrigent, a corrigent and the like to the medicinal component of the present invention, Tablets, coated tablets, granules, powders, capsules and the like can be produced by conventional methods. Such additives may be those commonly used in the art.
- excipients include lactose, sucrose, sodium chloride, glucose, starch, calcium carbonate, kaolin, microcrystalline cellulose, silicic acid As a binder, water, ethanol, propanol, simple syrup, glucose solution, starch solution, gelatin solution, carboxymethylcellulose, hydroxypropylcellulose, hydroxypropyl starch, methylcellulose, ethylcellulose, shellac, calcium phosphate, polyvinylpyrrolidone, etc.
- Disintegrants include dry starch, sodium alginate, agar powder, sodium bicarbonate, calcium carbonate, sodium lauryl sulfate, stearic acid monoglyceride, lactose, etc., and purified talc and stearate as lubricants Borax, polyethylene glycol, etc., as the corrigent may be mentioned sucrose, orange peel, citric acid, tartaric acid and the like.
- liquid preparations syrups, elixirs, etc.
- a corrigent, buffer, stabilizer, flavor, etc. to the medicinal ingredients of the present invention.
- the flavoring agent may be those listed above
- examples of the buffering agent include sodium citrate
- examples of the stabilizer include tragacanth, gum arabic, and gelatin.
- a pH adjuster When preparing an injection, add a pH adjuster, buffer, stabilizer, tonicity agent, local anesthetic, etc. to the medicinal component of the present invention, and inject subcutaneously, intramuscularly and intravenously by conventional methods.
- Agent can be produced.
- examples of the pH adjuster and buffer include sodium citrate, EDTA, thioglycolic acid, and thiolactic acid.
- examples of local anesthetics include procaine hydrochloride and lidocaine hydrochloride.
- the isotonizing agent include sodium chloride and glucose.
- the medicinal component of the present invention is added to a known pharmaceutical carrier such as polyethylene glycol, lanolin, cocoa butter, fatty acid triglyceride, and the like, and an interface such as Tween (registered trademark) as necessary. After adding an activator etc., it can manufacture by a conventional method.
- bases, stabilizers, wetting agents, preservatives and the like that are usually used for the medicinal components of the present invention are blended as necessary, and mixed and formulated by conventional methods.
- the base include liquid paraffin, white petrolatum, white beeswax, octyldodecyl alcohol, paraffin and the like.
- the preservative include methyl paraoxybenzoate, ethyl paraoxybenzoate, and propyl paraoxybenzoate.
- the ointment, cream, gel, paste or the like may be applied to a normal support by a conventional method.
- a woven fabric, nonwoven fabric, soft vinyl chloride, polyethylene, polyurethane film or foam sheet made of cotton, suf, chemical fiber is suitable.
- the amount of the cholestanol derivative and the anticancer agent in the preparation is generally preferably prepared in a preparation form in which the amount of the active ingredient is 0.0001 to 80% by weight in the preparation.
- the cancer chemotherapeutic agent of the present invention When used as a kit, the cholestanol derivative (1) formulated as described above or its cyclodextrin inclusion complex and a drug containing an anticancer agent are separately packaged and administered. Sometimes it can be designed to take and use each pharmaceutical formulation from each package. Each pharmaceutical preparation can also be packaged in a form suitable for each combined administration.
- the dose of the cancer chemotherapeutic agent of the present invention varies depending on the patient's weight, age, sex, symptom, dosage form, number of administrations, etc., but is usually an adult a day as a cholestanol derivative (1).
- the range is about 0.1 to 30 mg / kg, preferably 3 to 10 mg / kg per person, and the anticancer agents include their respective established doses or lower doses.
- the frequency of administration is not particularly limited, and can be administered once a day or divided into several times, but is preferably administered once a day. Moreover, when it is set as a kit, you may administer each single formulation simultaneously or at intervals.
- Example 1 Effect of Addition of Drug on Inhibition of Cancer Cell Growth
- Colon 26 cells (derived from mouse colon cancer) were seeded in 96-wells (1 ⁇ 10 4 cells / 50 ⁇ l, 10% FCS-RPMI medium / well) at 37 ° C. for 16 hours. Cultured.
- CDDP cisplatin
- L-OHP oxaliplatin
- PTX paclitaxel
- TXT docetaxel
- CPT-11 Irinotecan
- CPT-CD cyclophosphamide
- GC Cyclodextrin inclusion complex
- FCS ⁇ -medium: final concentration of 500 ⁇ M or less, 50 ⁇ l
- GC-CD was produced according to the method described in Example 1 (2) of Patent Document 4. That is, it was prepared by preparing an aqueous solution (40%) of hydroxypropyl- ⁇ -cyclodextrin, adding GC, stirring and mixing (80 ° C., 30 minutes). In addition, a control to which only FCS ( ⁇ )-medium was added was prepared as a control. Viable cells were measured with a cell counting kit (Dojin). The cell proliferation inhibition (CPI) rate (%) was determined by the following formula. The results are shown in FIG. 1 (FIGS. 1-A, 1-B, 1-C).
- Example 2 Growth Inhibitory Effect of Various Cancer Cells
- the experiment was conducted in the same manner as in Example 1 except that the colon 26 cells in Example 1 were changed to MKN45 (derived from human stomach cancer), NCIH226 (derived from human lung cancer) and Colo201 (derived from human colon cancer).
- the CPI rate (%) was measured.
- the results are shown in FIG. Further, as the cholestanol derivative, the above-mentioned GC except that the cyclodextrin inclusion compound of the compound (abbreviated as “GGC”) in which G is GlcNAc ⁇ 1,4-Gal ⁇ - in the formula (1) (the cholestanol compound is changed to GCC)
- FIG. 3 shows the results of measuring the CPI rate for the above cancer cells in the case of using the same method as that for CD production (abbreviated as “GGC-CD”).
- Example 3 Effect of drug addition on cancer cell growth inhibition in vivo
- Balb / c mice (6 weeks old, female) were used as target animals.
- Colon 26 cells were inoculated intraperitoneally at 1 ⁇ 10 4 cells / animal (day 0).
- physiological saline (Otsuka raw infusion)
- 500 ⁇ l was intraperitoneally administered, and the breeding was continued.
- the animals were dissected 19 days after the inoculation, and their mesentery and omentum weights were measured.
- 500 ⁇ l of physiological saline alone was administered.
- N 10; 10 in each group
- the results are shown in FIG.
- Colon 26 cells were inoculated intraperitoneally at 1 ⁇ 10 4 cells / animal (day 0).
- concentration of CDDP and / or GC-CD was adjusted with physiological saline (Otsuka raw food injection), 500 ⁇ l was intraperitoneally administered, and the breeding was continued.
- the animals were dissected 18 days after the inoculation, and the mesentery and body net weight were measured.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nanotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Abstract
Description
従って、従来の化学療法をしのぐ、さらなる副作用の軽減とより優れた有効性を有する、新しい併用化学療法及びそのための化学療法剤の開発が要望されている。
しかしながら、当該化合物が他の抗癌剤と併用された例は全く報告されていない。
1)下記一般式(1):
で表されるコレスタノール誘導体又はそのシクロデキストリン包接体と抗癌剤とを組み合わせてなる癌化学療法剤。
2)一般式(1)中、GがGlcNAc-Gal-又はGlcNAc-である前記1)の癌化学療法剤。
3)抗癌剤が、タキサン系抗癌剤、白金錯体抗癌剤、ペメトレキセド化合物及びフルオロウラシルからなる群より選択される1種以上である前記1)又は2)の癌化学療法剤。
4)抗癌剤が、パクリタキセル、ドセタキセル、ペメトレキセド、5-FU、シスプラチン、オキサリプラチン、サイクロフォスファミド及びイリノテカンからなる群から選択される1種以上である前記3)の癌化学療法剤。
5)抗癌剤が、タキサン系抗癌剤、ペメトレキセド化合物及びフルオロウラシルからなる群より選択される1種以上である前記1)又は2)の癌化学療法剤。
6)抗癌剤が、パクリタキセル、ドセタキセル、ペメトレキセド、5-FU、サイクロフォスファミド及びイリノテカンからなる群から選択される1種以上である前記5)の癌化学療法剤。
7)配合剤である前記1)~6)のいずれかの癌化学療法剤。
8)コレスタノール誘導体を含有してなる薬剤と抗癌剤を含有してなる薬剤からなるキットである前記1)~6)のいずれかの癌化学療法剤。
9)コレスタノール誘導体を含有してなる薬剤がリポソーム製剤である前記8)の癌化学療法剤。
10)癌化学療法剤を製造するための、下記一般式(1):
で表されるコレスタノール誘導体又はそのシクロデキストリン包接体と抗癌剤との組み合わせの使用。
11)抗癌剤が、タキサン系抗癌剤、ペメトレキセド化合物及びフルオロウラシルからなる群より選択される1種以上である前記10)の使用。
12)抗癌剤が、パクリタキセル、ドセタキセル、ペメトレキセド、5-FU、サイクロフォスファミド及びイリノテカンからなる群から選択される1種以上である前記11)の使用。
13)下記一般式(1):
で表されるコレスタノール誘導体又はそのシクロデキストリン包接体と抗癌剤とを組み合わせて投与することを特徴とする癌化学療法。
14)コレスタノール誘導体又はそのシクロデキストリン包接体と抗癌剤とを同時にあるいは時間を置いて別々に投与する前記13)の癌化学療法。
斯かるコレスタノール誘導体(1)のうち、GがGlcNAc-Gal-であるものは、好ましくはGlcNAcβ1,3-Galβ-又はGlcNAcβ1,4-Galβ-であり、GlcNAc-Gal-Glc-であるものは、好ましくはGlcNAcβ1,3-Galβ1,4-Glc-であり、Fuc-Gal-であるものは、好ましくはFucα1,3Gal-であり、Gal-Glc-であるものは、好ましくはGalβ1,4Glcβ-であり、Gal-であるものは、好ましくはGalβ-であり、GlcNAc-であるものは、好ましくはGlcNAcβ-である。
このうち、GがGlcNAc-Gal-、GlcNAc-であるものがより好ましく、GlcNAcβ1,4-Galβ-、GlcNAcβ-であるものが更に好ましい。
上記コレスタノール誘導体は、例えば、前記特許文献1-4に記載の方法又はこれに準じる方法により製造することができる。
斯かるリポソーム製剤は、本発明のコレスタノール誘導体、膜成分物質及び脂肪族又は芳香族アミンを含有するリポソームであるのが好ましい。
リポソーム製剤中のコレスタノール誘導体の含有量は、膜成分物質1モルに対して、0.3~2.0モル、好ましくは0.8~1.5モルであるのが望ましい。
当該アミンは、膜成分物質(リン脂質)1モルに対して、0.04~0.15モル、好ましくは0.1~0.15モル含有するのが好ましい。
具体的には、サイクロフォスファミド(Cyclophosphamide)、イフォスファミド(Ifosfamide)、メルファラン(Melphalan, L-PAM)、ブスルファン(Busulfan)、カルボキノン(Carboquone)等のアルキル化剤;6-メルカプトプリン(6-Mercaptopurine, 6-MP)、メトトレキサート(Methotrexate, MTX)、5-フルオロウラシル(5-Fluorouracil, 5-FU)、テガファー(Tegafur)、エノシタビン(Enocitabine, BHAC)、ペメトレキセド化合物(ペメトレキセド,Pemetrexed, MTA)等の代謝拮抗剤;アクチノマイシンD (Actinomycin D)、ダウノルビシン(Daunorubicin)、ブレオマイシン(Bleomycin)、ペプレオマイシン(Peplomycin)、マイトマイシンC(Mitomycin C)、アクラルビシン(Aclarubicin)、ネオカルチノスタチン(Neocarzinostatin, NCS)等の抗癌性抗生物質;ビンクリスチン(Vincristine)、ビンデシン(Vindesine)、ビンブラスチン (Vinblastine)、タキサン系抗癌剤(タキソテール(Docetaxel, ドセタキセル)、タキソール(Paclitaxel, TXL, パクリタキセル)等)、イリノテカン(Irinotecan,CPT-11)等の植物アルカロイド;シスプラチン(Cisplatin, CDDP)、カルボプラチン(Carboplatin)、オキサリプラチン(Oxaliplatin, L-OHP)等の白金化合物等が挙げられ、これらを1種又は2種以上組み合わせて用いることができる。
本発明の癌化学療法剤の適用により有効に治療可能な癌は、制限されるものではないが、特に胃癌、大腸癌、膵臓癌、子宮癌、卵巣癌、肺臓癌、胆嚢癌、食道癌、肝臓癌、乳癌、中皮腫、前立腺癌などの悪性腫瘍が挙げられる。
斯かる製剤の投与形態も限定されるものではなく、剤形に応じて適切な経路により投与すればよく、例えば、注射剤は静脈内、筋肉内、皮下、皮内腹腔内投与され、固形製剤は経口、経腸投与され得る。
例えば、経口用固形製剤を調製する場合は、本発明の薬効成分に賦形剤、必要に応じて結合剤、崩壊剤、滑沢剤、着色剤、矯味剤、矯臭剤等を加えた後、常法により錠剤、被覆錠剤、顆粒剤、散剤、カプセル剤等を製造することができる。そのような添加剤としては、当該分野で一般的に使用されるものでよく、例えば、賦形剤としては、乳糖、白糖、塩化ナトリウム、ブドウ糖、デンプン、炭酸カルシウム、カオリン、微結晶セルロース、珪酸等を、結合剤としては、水、エタノール、プロパノール、単シロップ、ブドウ糖液、デンプン液、ゼラチン液、カルボキシメチルセルロース、ヒドロキシプロピルセルロース、ヒドロキシプロピルスターチ、メチルセルロース、エチルセルロース、シェラック、リン酸カルシウム、ポリビニルピロリドン等を、崩壊剤としては、乾燥デンプン、アルギン酸ナトリウム、カンテン末、炭酸水素ナトリウム、炭酸カルシウム、ラウリル硫酸ナトリウム、ステアリン酸モノグリセリド、乳糖等を、滑沢剤としては精製タルク、ステアリン酸塩、ホウ砂、ポリエチレングリコール等を、矯味剤としては白糖、橙皮、クエン酸、酒石酸等を挙げることができる。
投与回数は、特に限定されず、一日1回或いは数回に分けて投与することができるが、一日1回投与するのが好ましい。また、キットとする場合は、それぞれ単独の製剤を同時に或いは間隔を空けて投与してもよい。
colon26細胞(マウス大腸癌由来)を、96穴ウェルに蒔き(1x104 cells/50μl、10%FCS-RPMI medium/well)、37oCで16時間培養した。公知の抗癌剤(シスプラチン(「CDDP」と略す)、オキサリプラチン(「L-OHP」と略す)、フルオロウラシル(5-FU)、パクリタキセル(TXL;「PTX」と略す)、ドセタキセル(TXT;「DTX」と略す)、イリノテカン(CPT-11;「CPT」と略す)、または、サイクロホスファミド(「CPA」と略す))および/または式(1)においてGがGlcNAcβ-であるコレスタノール誘導体(「GC」と略す)のシクロデキストリン包接体(「GC-CD」と略す)を各ウェルに加え(FCS(-)-mediumで倍数希釈:終濃度 500μM以下、50μl)、37oCで2日間培養する。尚、GC-CDは、前記特許文献4の実施例1の(2)に記載の方法に準じて製造した。すなわち、ヒドロキシプロピル-β-シクロデキストリンの水溶液(40%)を調整し、GCを添加して、攪拌・混合(80℃、30分)して作製した。
また、コントロールとして、FCS(-)-mediumのみを加えたものを準備した。Cell counting kit(Dojin)で生細胞を測定した。
細胞増殖抑制率(Cell proliferation inhibition(CPI) rate)(%)を、次式で求めた。結果を図1(図1-A、図1-B、図1-C)に示す。
実施例1のcolon26細胞をMKN45(ヒト胃癌由来)、NCIH226(ヒト肺癌由来)及びColo201(ヒト大腸癌由来)に変えて、実施例1と同様に実験を行い、CPI rate(%)を測定した。結果を図2に示す。
また、コレスタノール誘導体として、式(1)においてGがGlcNAcβ1,4-Galβ-である化合物(「GGC」と略す)のシクロデキストリン包接体(コレスタノール化合物をGCCに変えた以外は、上記GC-CDの製造方法と同様にして製造した;「GGC-CD」と略す)を用いた場合の、上記癌細胞に対するCPI rateを測定した結果を図3に示す。
以下の実施例では、対象動物として、Balb/cマウス(6週齢、メス)を使用した。
(1)Colon26細胞を、1x104cells/匹にて腹腔内に接種した(0日)。接種後1日目に、それぞれCDDPおよび/またはGC-CDを生理的食塩水(大塚生食注)にて濃度調整し、500μlを腹腔内投与して、そのまま飼育を続けた。接種後19日目に解剖し、その腸間膜および大網重量を測定した。コントロール群には、生理的食塩水のみを500μl投与した。(n=10;各群10匹)
結果を図4に示す。
結果を図5に示す。
結果を図6に示す。
対象動物として、Balb/cマウス(6週齢、メス)を使用した。Colon26細胞を、1x104cells/匹にて腹腔内に接種した(0日)。接種後2日目および/または3日目(投与スケジュールは図7の凡例参照)に、それぞれCDDPおよび/またはGC-CDを生理的食塩水(大塚生食注)にて濃度調整し、500μlを腹腔内投与して、そのまま飼育を続け、接種後43日目までの生存日数を比較した。コントロール群には、生理的食塩水のみを500μl投与した。(n=10;各群10匹)
結果を図7に示す。
対象動物として、Balb/cマウス(6週齢、メス)を使用した。Colon26細胞を、5x104cells/匹にて皮下注射にて投与した(0日)。腫瘍の径が4mm程度になったことを確認し(接種後7-10日目)、それぞれCDDPおよび/またはGGC-CDを生理的食塩水(大塚生食注)にて濃度調整し、200μlを尾静脈投与して、そのまま飼育を続け、接種後21日目までの腫瘍径を経時的に測定し、体積を求めた。コントロール群には、生理食塩水のみを200μl投与した。(n=7;各群7匹)
結果を図8に示す。
対象動物として、Balb/cマウス(6週齢、メス)を使用した。Colon26細胞を、5x104cells/匹にて腹腔内投与した(0日)。接種後に、それぞれCDDPおよび/またはGC-CDあるいはGGC-CDを生理的食塩水(大塚生食注)にて濃度調整し、200μlを尾静脈投与して、そのまま飼育を続け、接種後14日目に解剖し、肺の腫瘍結節数を測定した。コントロール群には、何も投与しなかった。(n=10;各群10匹)
結果を図9に示す。
Claims (14)
- 一般式(1)中、GがGlcNAc-Gal-又はGlcNAc-である請求項1記載の癌化学療法剤。
- 抗癌剤が、タキサン系抗癌剤、白金錯体抗癌剤、ペメトレキセド化合物及びフルオロウラシルからなる群より選択される1種以上である請求項1又は2記載の癌化学療法剤。
- 抗癌剤が、パクリタキセル、ドセタキセル、アリムタ、5-FU、シスプラチン、オキサリプラチン、サイクロフォスファミド及びイリノテカンからなる群から選択される1種以上である請求項3記載の癌化学療法剤。
- 抗癌剤が、タキサン系抗癌剤、ペメトレキセド化合物及びフルオロウラシルからなる群より選択される1種以上である請求項1又は2記載の癌化学療法剤。
- 抗癌剤が、パクリタキセル、ドセタキセル、ペメトレキセド、5-FU、サイクロフォスファミド及びイリノテカンからなる群から選択される1種以上である請求項5記載の使用。
- 配合剤である請求項1~6記載の癌化学療法剤。
- コレスタノール誘導体を含有してなる薬剤と抗癌剤を含有してなる薬剤からなるキットである請求項1~6記載の癌化学療法剤。
- コレスタノール誘導体を含有してなる薬剤がリポソーム製剤である請求項8記載の癌化学療法剤。
- 抗癌剤が、タキサン系抗癌剤、ペメトレキセド化合物及びフルオロウラシルからなる群より選択される1種以上である請求項10記載の使用。
- 抗癌剤が、パクリタキセル、ドセタキセル、ペメトレキセド、5-FU、サイクロフォスファミド及びイリノテカンからなる群から選択される1種以上である請求項11記載の使用。
- コレスタノール誘導体又はそのシクロデキストリン包接体と抗癌剤とを同時にあるいは時間を置いて別々に投与する請求項13記載の癌化学療法。
Priority Applications (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
UAA201111603A UA101884C2 (uk) | 2008-03-05 | 2009-03-09 | Протираковий хіміотерапевтичний засіб, що містить похідну сполуки холестанолу та іринотекан |
DK09841052T DK2404608T3 (en) | 2009-03-04 | 2009-09-03 | CHOLESTANOLDERIVAT for combined use |
ES09841052.5T ES2534800T3 (es) | 2009-03-04 | 2009-09-03 | Derivado de colestanol para uso combinado |
NZ594996A NZ594996A (en) | 2009-03-04 | 2009-09-03 | Cholestanol derivative for combined use |
MX2011009291A MX2011009291A (es) | 2009-03-04 | 2009-09-03 | Derivado de colestanol para su uso combinado. |
RU2011140172/15A RU2519186C2 (ru) | 2009-03-04 | 2009-09-03 | Производное соединение холестанола для комбинированного применения |
PL09841052T PL2404608T3 (pl) | 2009-03-04 | 2009-09-03 | Pochodna cholestanolu do zastosowania w terapii skojarzonej |
CA2754075A CA2754075A1 (en) | 2009-03-04 | 2009-09-03 | Cholestanol derivative for combined use |
CN2009800001957A CN101969961B (zh) | 2008-03-05 | 2009-09-03 | 胆甾烷醇衍生物的合用用途 |
AU2009341417A AU2009341417A1 (en) | 2009-03-04 | 2009-09-03 | Cholestanol derivative for combined use |
SI200931183T SI2404608T1 (sl) | 2009-03-04 | 2009-09-03 | Holestanolni derivat za kombinirano uporabo |
BRPI0924525A BRPI0924525A2 (pt) | 2008-03-05 | 2009-09-03 | "derivativos de colestanol para uso combinado" |
JP2011502510A JP5480241B2 (ja) | 2009-03-04 | 2009-09-03 | コレスタノール誘導体の併用用途 |
EP09841052.5A EP2404608B1 (en) | 2009-03-04 | 2009-09-03 | Cholestanol derivative for combined use |
ZA2011/05529A ZA201105529B (en) | 2009-03-04 | 2011-07-27 | Cholestanol derivative for combined use |
IL214319A IL214319A (en) | 2009-03-04 | 2011-07-28 | Chemotherapeutic agent for cancer containing cholesterol derivative and anticancer agent |
HK12100638.4A HK1160019A1 (en) | 2009-03-04 | 2012-01-19 | Cholestanol derivative for combined use |
HRP20150418TT HRP20150418T1 (hr) | 2008-03-05 | 2015-04-14 | Derivat kolestanola za kombiniranu uporabu |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2009/000985 WO2009110235A1 (ja) | 2008-03-05 | 2009-03-04 | コレスタノール誘導体の併用用途 |
JPPCT/JP2009/000985 | 2009-03-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010100686A1 true WO2010100686A1 (ja) | 2010-09-10 |
Family
ID=42710286
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2009/004353 WO2010100686A1 (ja) | 2008-03-05 | 2009-09-03 | コレスタノール誘導体の併用用途 |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP2404608B1 (ja) |
KR (1) | KR20110122682A (ja) |
AU (1) | AU2009341417A1 (ja) |
CA (1) | CA2754075A1 (ja) |
CY (1) | CY1116340T1 (ja) |
DK (1) | DK2404608T3 (ja) |
ES (1) | ES2534800T3 (ja) |
HK (1) | HK1160019A1 (ja) |
IL (1) | IL214319A (ja) |
MX (1) | MX2011009291A (ja) |
NZ (1) | NZ594996A (ja) |
PL (1) | PL2404608T3 (ja) |
PT (1) | PT2404608E (ja) |
RU (1) | RU2519186C2 (ja) |
SI (1) | SI2404608T1 (ja) |
TW (1) | TWI461199B (ja) |
WO (1) | WO2010100686A1 (ja) |
ZA (1) | ZA201105529B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017015584A1 (en) * | 2015-07-22 | 2017-01-26 | Spectrum Pharmaceuticals, Inc. | A ready-to-use formulation for vincristine sulfate liposome injection |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5782310A (en) | 1980-11-11 | 1982-05-22 | Tanabe Seiyaku Co Ltd | Production of liposome preparation |
JPS6012127A (ja) | 1983-06-30 | 1985-01-22 | Dai Ichi Seiyaku Co Ltd | リポソ−ムの製法 |
JPS6058915A (ja) | 1983-09-12 | 1985-04-05 | Fujisawa Pharmaceut Co Ltd | 薬物含有脂質小胞体製剤 |
JPH01117824A (ja) | 1987-10-30 | 1989-05-10 | Terumo Corp | リポソームの製法 |
JPH01167218A (ja) | 1987-12-22 | 1989-06-30 | Sumitomo Electric Ind Ltd | 超電導薄膜の作製方法 |
JPH0429925A (ja) | 1990-05-28 | 1992-01-31 | Terumo Corp | リポソームの製法 |
JPH0987168A (ja) | 1995-09-20 | 1997-03-31 | Nippon Oil & Fats Co Ltd | リポソーム用混合脂質及びリポソーム分散液 |
JPH1160592A (ja) | 1997-08-19 | 1999-03-02 | Nippon Koutai Kenkyusho:Kk | コレスタノール化合物及びこれを含有する医薬 |
JP2000191685A (ja) | 1998-12-24 | 2000-07-11 | Nippon Koutai Kenkyusho:Kk | コレスタノール化合物及びこれを含有する医薬 |
WO2005007172A1 (ja) | 2003-07-17 | 2005-01-27 | Otsuka Pharmaceutical Co., Ltd. | 配糖体含有リポソーム |
WO2005118071A2 (en) * | 2004-05-28 | 2005-12-15 | Altana Pharma Ag | Tetrahydropyridothiophenes |
WO2007026869A1 (ja) | 2005-09-02 | 2007-03-08 | Otsuka Pharmaceutical Co., Ltd. | 抗癌剤 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2240793C1 (ru) * | 2003-12-02 | 2004-11-27 | Лимонов Виктор Львович | Противоопухолевое средство |
TWI492759B (zh) * | 2008-03-05 | 2015-07-21 | Otsuka Pharma Co Ltd | 膽甾烷醇衍生物之併用用途 |
-
2009
- 2009-09-03 NZ NZ594996A patent/NZ594996A/en unknown
- 2009-09-03 AU AU2009341417A patent/AU2009341417A1/en not_active Abandoned
- 2009-09-03 MX MX2011009291A patent/MX2011009291A/es active IP Right Grant
- 2009-09-03 EP EP09841052.5A patent/EP2404608B1/en not_active Not-in-force
- 2009-09-03 PT PT98410525T patent/PT2404608E/pt unknown
- 2009-09-03 PL PL09841052T patent/PL2404608T3/pl unknown
- 2009-09-03 CA CA2754075A patent/CA2754075A1/en not_active Abandoned
- 2009-09-03 RU RU2011140172/15A patent/RU2519186C2/ru not_active IP Right Cessation
- 2009-09-03 ES ES09841052.5T patent/ES2534800T3/es active Active
- 2009-09-03 KR KR1020117019434A patent/KR20110122682A/ko not_active Application Discontinuation
- 2009-09-03 DK DK09841052T patent/DK2404608T3/en active
- 2009-09-03 SI SI200931183T patent/SI2404608T1/sl unknown
- 2009-09-03 WO PCT/JP2009/004353 patent/WO2010100686A1/ja active Application Filing
- 2009-09-04 TW TW098129920A patent/TWI461199B/zh not_active IP Right Cessation
-
2011
- 2011-07-27 ZA ZA2011/05529A patent/ZA201105529B/en unknown
- 2011-07-28 IL IL214319A patent/IL214319A/en not_active IP Right Cessation
-
2012
- 2012-01-19 HK HK12100638.4A patent/HK1160019A1/xx not_active IP Right Cessation
-
2015
- 2015-04-23 CY CY20151100377T patent/CY1116340T1/el unknown
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5782310A (en) | 1980-11-11 | 1982-05-22 | Tanabe Seiyaku Co Ltd | Production of liposome preparation |
JPS6012127A (ja) | 1983-06-30 | 1985-01-22 | Dai Ichi Seiyaku Co Ltd | リポソ−ムの製法 |
JPS6058915A (ja) | 1983-09-12 | 1985-04-05 | Fujisawa Pharmaceut Co Ltd | 薬物含有脂質小胞体製剤 |
JPH01117824A (ja) | 1987-10-30 | 1989-05-10 | Terumo Corp | リポソームの製法 |
JPH01167218A (ja) | 1987-12-22 | 1989-06-30 | Sumitomo Electric Ind Ltd | 超電導薄膜の作製方法 |
JPH0429925A (ja) | 1990-05-28 | 1992-01-31 | Terumo Corp | リポソームの製法 |
JPH0987168A (ja) | 1995-09-20 | 1997-03-31 | Nippon Oil & Fats Co Ltd | リポソーム用混合脂質及びリポソーム分散液 |
JPH1160592A (ja) | 1997-08-19 | 1999-03-02 | Nippon Koutai Kenkyusho:Kk | コレスタノール化合物及びこれを含有する医薬 |
JP2000191685A (ja) | 1998-12-24 | 2000-07-11 | Nippon Koutai Kenkyusho:Kk | コレスタノール化合物及びこれを含有する医薬 |
WO2005007172A1 (ja) | 2003-07-17 | 2005-01-27 | Otsuka Pharmaceutical Co., Ltd. | 配糖体含有リポソーム |
WO2005118071A2 (en) * | 2004-05-28 | 2005-12-15 | Altana Pharma Ag | Tetrahydropyridothiophenes |
WO2007026869A1 (ja) | 2005-09-02 | 2007-03-08 | Otsuka Pharmaceutical Co., Ltd. | 抗癌剤 |
Non-Patent Citations (2)
Title |
---|
METHODS OF BIOCHEMICAL ANALYSIS, vol. 33, 1988, pages 337 |
See also references of EP2404608A4 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017015584A1 (en) * | 2015-07-22 | 2017-01-26 | Spectrum Pharmaceuticals, Inc. | A ready-to-use formulation for vincristine sulfate liposome injection |
US11559486B2 (en) | 2015-07-22 | 2023-01-24 | Acrotech Biopharma, LLC | Ready-to-use formulation for Vincristine Sulfate Liposome Injection |
Also Published As
Publication number | Publication date |
---|---|
EP2404608A4 (en) | 2013-05-22 |
IL214319A0 (en) | 2011-09-27 |
TW201032812A (en) | 2010-09-16 |
CA2754075A1 (en) | 2010-09-10 |
PL2404608T3 (pl) | 2015-08-31 |
TWI461199B (zh) | 2014-11-21 |
KR20110122682A (ko) | 2011-11-10 |
NZ594996A (en) | 2014-02-28 |
IL214319A (en) | 2015-08-31 |
ZA201105529B (en) | 2012-09-26 |
SI2404608T1 (sl) | 2015-06-30 |
RU2519186C2 (ru) | 2014-06-10 |
AU2009341417A1 (en) | 2011-09-22 |
PT2404608E (pt) | 2015-07-21 |
DK2404608T3 (en) | 2015-04-27 |
MX2011009291A (es) | 2011-09-30 |
HK1160019A1 (en) | 2012-08-10 |
EP2404608A1 (en) | 2012-01-11 |
CY1116340T1 (el) | 2017-02-08 |
ES2534800T3 (es) | 2015-04-29 |
EP2404608B1 (en) | 2015-04-01 |
RU2011140172A (ru) | 2013-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2786754B1 (en) | Combination therapy with a mitotic inhibitor | |
US20150374730A1 (en) | Cholestanol derivative for combined use | |
TWI598095B (zh) | 治療或緩解高齡或末期癌症患者用之醫藥組合物 | |
WO2010143986A1 (en) | Combined therapy of colorectal carcinoma | |
WO2010100686A1 (ja) | コレスタノール誘導体の併用用途 | |
JP5480241B2 (ja) | コレスタノール誘導体の併用用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980000195.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09841052 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2011502510 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009841052 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12011501652 Country of ref document: PH |
|
ENP | Entry into the national phase |
Ref document number: 20117019434 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11108511 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2754075 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2011/009291 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 594996 Country of ref document: NZ Ref document number: 2009341417 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2009341417 Country of ref document: AU Date of ref document: 20090903 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2011140172 Country of ref document: RU Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: PI0924525 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: PI0924525 Country of ref document: BR Kind code of ref document: A2 Effective date: 20110825 |